Neogen (NEOG) Expected to Announce Earnings on Wednesday

Neogen (NASDAQ:NEOG) is expected to be announcing its earnings results before the market opens on Wednesday, April 9th. Analysts expect Neogen to post earnings of $0.13 per share and revenue of $225.27 million for the quarter. Neogen has set its FY 2025 guidance at EPS.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings data on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.12. The business had revenue of $231.30 million for the quarter, compared to analysts’ expectations of $227.16 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm’s revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.11 EPS. On average, analysts expect Neogen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Neogen Stock Performance

Shares of Neogen stock opened at $7.80 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -3.56 and a beta of 1.57. The stock’s 50-day moving average is $9.80 and its 200-day moving average is $12.44. Neogen has a one year low of $7.68 and a one year high of $18.58.

Insiders Place Their Bets

In other news, CEO John Edward Adent bought 23,035 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, with a total value of $254,076.05. Following the acquisition, the chief executive officer now owns 269,164 shares in the company, valued at $2,968,878.92. This trade represents a 9.36 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David H. Naemura bought 14,800 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was purchased at an average price of $11.11 per share, with a total value of $164,428.00. Following the completion of the purchase, the chief financial officer now directly owns 61,434 shares in the company, valued at $682,531.74. The trade was a 31.74 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Guggenheim started coverage on Neogen in a research report on Thursday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Piper Sandler restated a “neutral” rating and set a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.